Shore Capital restated their sell rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Wednesday morning.

Several other brokerages also recently weighed in on AZN. BNP Paribas reaffirmed a neutral rating and issued a GBX 5,100 ($62.99) target price on shares of AstraZeneca plc in a report on Sunday, January 15th. Investec initiated coverage on shares of AstraZeneca plc in a report on Monday, January 23rd. They issued a hold rating and a GBX 4,600 ($56.81) target price on the stock. Liberum Capital reaffirmed a hold rating and issued a GBX 5,200 ($64.22) target price on shares of AstraZeneca plc in a report on Thursday, December 8th. Goldman Sachs Group Inc set a GBX 3,900 ($48.17) price objective on shares of AstraZeneca plc and gave the stock a sell rating in a report on Friday, February 17th. Finally, Deutsche Bank AG reissued a buy rating and set a GBX 6,000 ($74.10) price objective on shares of AstraZeneca plc in a report on Tuesday, December 13th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,018.36 ($61.98).

Shares of AstraZeneca plc (LON:AZN) opened at 4871.50 on Wednesday. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The stock’s 50 day moving average price is GBX 4,617.49 and its 200-day moving average price is GBX 4,602.58. The company’s market cap is GBX 61.64 billion.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/shore-capital-reiterates-sell-rating-for-astrazeneca-plc-azn.html

Your IP Address:

The company also recently disclosed a dividend, which was paid on Monday, March 20th. Stockholders of record on Thursday, February 16th were given a GBX 150.20 ($1.86) dividend. This represents a dividend yield of 3.52%. The ex-dividend date of this dividend was Thursday, February 16th. This is a positive change from AstraZeneca plc’s previous dividend of $68.70.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.